FDA-approved1,4,5,6Evidence: Large human trialsMetabolic and weight · Heart and blood vessels · Liver

Semaglutide1

Also called Wegovy, Ozempic, Rybelsus3

Key takeaway

Semaglutide is a lab-made version of GLP-1, a gut hormone that helps regulate appetite, and is the active ingredient in Ozempic, Rybelsus and Wegovy.1,4,5,6 It is FDA-approved. The current Wegovy label covers long-term weight reduction, lowering the risk of major cardiovascular events in adults with heart disease and obesity or overweight, and a liver disease called MASH under accelerated approval.1 Those approvals rest on large randomized trials, including a cardiovascular trial of 17,604 adults described in the label.1 FDA says compounded and other unapproved semaglutide products are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before they are marketed.10

Semaglutide at a glance

What it isA GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1
FDA statusFDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.1,4,5,6
Human evidenceLarge randomized, placebo-controlled trials described in the Wegovy label, covering cardiovascular events, weight and MASH.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is semaglutide?

Semaglutide is a lab-made peptide that mimics GLP-1, a hormone released by the gut. The Wegovy label describes it as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1

Drugs@FDA lists it as the active ingredient of three Novo Nordisk brands: Ozempic, Rybelsus and Wegovy.4,5,6

How does semaglutide work?

The label states that semaglutide binds to and activates the GLP-1 receptor, the target of the natural hormone, and that GLP-1 is a physiological regulator of appetite and calorie intake.1

The label also states that the exact mechanism behind its cardiovascular risk reduction has not been established, and that its mechanism in MASH is not fully understood.1

What do human studies show?

The Wegovy label describes the trials behind its approved uses. In the cardiovascular trial, 17,604 adults with established heart or blood-vessel disease and obesity or overweight, but no diabetes, were randomized to Wegovy or placebo alongside standard care.1

Over a median follow-up of 41.8 months, a first major cardiovascular event (cardiovascular death, non-fatal heart attack or non-fatal stroke) occurred in 6.5% of the Wegovy group and 8% of the placebo group, according to the label.1

The label reports that 31% of the Wegovy group and 27% of the placebo group permanently stopped the study drug during that trial.1

The label also describes several randomized, placebo-controlled weight trials lasting 68 or 72 weeks, including one of 1,961 adults without type 2 diabetes, and a MASH trial whose week-72 analysis included 800 adults.1

What the evidence base contains

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.1
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.1
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is semaglutide FDA-approved?

Yes. Drugs@FDA records list these original approval dates: Ozempic on December 5, 2017, Rybelsus on September 20, 2019, and Wegovy on June 4, 2021. A further Wegovy application was approved on December 22, 2025.4,5,6,7

The Wegovy label cited here (DailyMed SPL version 19, published June 30, 2026) states that Wegovy is indicated, with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition.1

The label limits some uses to specific Wegovy products, including use in children aged 12 and older with obesity.1

The label also lists noncirrhotic MASH with moderate to advanced liver fibrosis in adults. It states that this indication was granted under accelerated approval and that continued approval may depend on a confirmatory trial.1

On March 19, 2026, FDA announced approval of Wegovy HD for weight reduction and long-term maintenance in certain adults.2

The label carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1

Other warnings in the label cover acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic eye complications in people with type 2 diabetes, increased heart rate and aspiration during anesthesia or deep sedation.1

In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines.8

FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, says some compounders sell salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients from those in the approved drugs, and that FDA is not aware of any lawful basis for compounding with them.10

The same page reports 990 adverse-event reports associated with compounded semaglutide received as of May 31, 2026, and describes counterfeit Ozempic and products falsely labeled as being for research purposes or not for human consumption.10

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.9

Timeline

  1. FDA approves Ozempic, the first semaglutide product, according to Drugs@FDA.4
  2. FDA approves Rybelsus, according to Drugs@FDA.5
  3. FDA approves Wegovy, according to Drugs@FDA.6
  4. FDA approves a further Wegovy application, according to Drugs@FDA.7
  5. FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.8
  6. FDA announces approval of Wegovy HD.2
  7. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.9
  8. DailyMed publishes the Wegovy label version cited on this page.1
  9. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10

What is still unknown?

Whether the cardiovascular benefit applies to lower-risk groups: the label’s trial enrolled only adults aged 45 or older with established cardiovascular disease and no diabetes.1

Whether the MASH indication will be confirmed: the label says continued approval for that use may depend on a confirmatory trial.1

Whether semaglutide causes thyroid C-cell tumors in humans, which the label says has not been determined.1

What is in compounded, counterfeit or so-called research products, which FDA says it does not review before they reach the market.10

Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.9

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Semaglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Semaglutide are the records PeptideScanner has selected and published, not every registration or paper about Semaglutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence questions

Start with the question you have

Open the cited status, reviewed human evidence, unresolved limits, or profile changes.

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Ozempic, Rybelsus and Wegovy. The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.↗↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed August 18, 2026 · Review version 1.

Review source snapshots checked August 18, 2026 · Integrity checked August 19, 2026.

A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.↗↗

What the reviewed sources report

In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.↗↗

What remains unresolved?

  • How do benefits and harms change after discontinuation, across populations excluded from these trials, and over longer follow-up?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Wegovy injection and tablets · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

For adults with established cardiovascular disease and obesity or overweight, the label covers cardiovascular-risk reduction with injection or tablets. Both formulations cover weight management in adults with obesity, or overweight with a weight-related condition. Injection additionally covers weight management in children aged twelve years and older with obesity, and noncirrhotic MASH with F2–F3 fibrosis in adults. The MASH indication has accelerated approval requiring confirmation of clinical benefit; it does not apply to the tablets. Label: 1 ↗

Which safety limits matter?

The boxed warning reports thyroid C-cell tumors in rodents, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, MEN 2 and hypersensitivity. Warnings address pancreatitis, gallbladder disease, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, retinopathy complications, increased heart rate and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30

Label ZIP SHA-256: a8c57f3e8cf2c89501ac3b6077dd7480fb4bf72bb0b42135078f0d3a1f20f8f8. Extracted XML SHA-256: 2f2c51a1fdf57a3a2459f340abfbe1e0283e5c8849d3a844db8c28ede302f6b3.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Semaglutide?

Manually reviewed August 18, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.12

Bottom line from this bounded source set

In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.12

Reviewed study record

STEP 1 weight-management trial

Design

A double-blind, randomized, placebo-controlled trial followed participants for 68 weeks alongside a lifestyle intervention.1

Population

The trial enrolled 1,961 adults with obesity, or overweight plus at least one weight-related condition, who did not have diabetes.1

Outcomes reported

Mean body-weight change at 68 weeks was -14.9% in the semaglutide group and -2.4% with placebo. Gastrointestinal events were common, and treatment discontinuation for gastrointestinal events was more frequent with semaglutide.1

Limitations

The sponsor-funded trial combined treatment with lifestyle intervention, excluded people with diabetes, and does not by itself establish outcomes after treatment stops.1

Reviewed study record

SELECT cardiovascular-outcomes trial

Design

A multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial assessed a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.2

Population

The trial enrolled 17,604 adults age 45 or older with established cardiovascular disease and overweight or obesity, but no history of diabetes.2

Outcomes reported

A primary cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group; the reported hazard ratio was 0.80. Permanent discontinuation because of adverse events occurred in 16.6% and 8.2%, respectively.2

Limitations

The sponsor-funded findings apply to people with preexisting cardiovascular disease and without diabetes; they do not answer primary prevention for lower-risk populations.2

Reviewed source set

  1. PubMed · 33567185Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗PubMed PMID 33567185 · EFetch XML reviewed 2026-08-18 · payload SHA-256 b3cf6a18c3906c27475c4a49d31f5741bf40fa056afc62f07d07fa54dbff28c4
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2032183. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 37952131Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗PubMed PMID 37952131 · EFetch XML reviewed 2026-08-18 · payload SHA-256 dabd7cd9d6c08b9c07da39a19d0b48266bfb7ddbbaacefe2e11025d105708245
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2307563. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-16 · Preserved version 1

FDA revisited the psychiatric-safety warning

On January 13, 2026, FDA requested removal of the suicidal-behavior and ideation warning from Wegovy labeling after its review found no increased risk. This records the agency’s request, not a claim that every label version has changed. FDA PDF pp. 1 ↗

More findings and the sources behind them

Selected FDA safety communications, read alongside the separately preserved product-label account and human evidence review.

What supported that finding

FDA combined 91 placebo-controlled trials involving 107,910 participants and examined a separate Sentinel claims cohort. These are class-wide analyses, not a dedicated trial of this peptide or a finding about every possible adverse effect. FDA PDF pp. 2, 3 ↗

The chemical form matters

FDA distinguishes semaglutide sodium and acetate from the active ingredient in approved drugs; it lacks information establishing the same chemical and pharmacologic properties. Evidence about an approved product should not be transferred automatically to those salts. FDA source ↗

What remains to be checked

  • Reconcile each current product and formulation label with subsequent safety and indication changes.
  • Appraise remaining eligible trial reports and follow-up studies; this update does not complete the literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA January 2026 GLP-1 psychiatric-safety communication ↗

    Source dated 2026-01-13; retrieved 2026-09-16.

    • What Is FDA Doing? · PDF pp. 1 of 3
    • What Did FDA Find? · PDF pp. 2, 3 of 3

    SHA-256: d2cc0d43605a9300646146c86f0fd4b84611ada2272de7e65425f33fb7aae53c

  • FDA concerns with unapproved GLP-1 drugs ↗

    Source dated 2026-09-01; retrieved 2026-09-16.

    • Concerns with compounded versions of these drugs
    • Salt forms should not be used to compound semaglutide
    • Adverse events related to compounded versions of semaglutide and tirzepatide
    • Retatrutide and cagrilintide cannot be used in compounding

    SHA-256: bfb6cd2a11e3f8e20bedfeed0e0d554205c76dd83f473956deb82afc186e51cc

Open versioned findings and source records →

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The initial Ozempic review concerns type 2 diabetes

EMA’s December 2017 assessment reports improvements in HbA1c and weight in controlled trials and a separate cardiovascular trial in people at high cardiovascular risk. It does not summarize later obesity, kidney or other indication-specific programs. EMA PDF pp. 154, 155 ↗

More findings, study links and document coverage

Cardiovascular outcomes were not uniformly improved

The review described benefit on some cardiovascular outcomes but neutral findings for cardiovascular death and all-cause death. It also cautioned against extrapolating the two-year high-risk trial to lower-risk populations. EMA PDF pp. 154, 155 ↗

Retinopathy was an observed safety signal

Serious retinopathy complications were more frequent with semaglutide in the reviewed trial, especially among participants with pre-existing retinopathy receiving insulin. EMA treated the mechanism as uncertain rather than proving a single explanation. EMA PDF pp. 147, 149, 155 ↗

Harms and duration matter alongside average benefit

Gastrointestinal adverse effects were frequent and clinically relevant. EMA also noted that two years is relatively short for chronic diabetes treatment, supporting longer follow-up rather than assuming that trial results settle every long-term risk. EMA PDF pp. 154, 155 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Ozempic : EPAR - Public assessment report ↗

    Selected sections reviewed · ema-14075 · Document/feed date: 2018-02-21

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Ozempic · EMEA/H/C/004174 · Document dated 2017-12-14. Identity checked on PDF pp. 1.

    Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.

    Retrieved 2026-09-19. Read PDF pages: 1, 147, 149, 154, 155 of 156. SHA-256: 71a57c0097238e05c51a99f58ace2036ea8d91ff70356300bc41573892a60a84.

    Feed-listed application (not a verified association): EMEA/H/C/004174.

Remaining work

  • Review Wegovy obesity, subsequent cardiovascular and kidney assessments as distinct indication-specific programs.
  • Reconcile later retinopathy evidence and formulation-specific safety updates with the original Ozempic assessment.

Open versioned document coverage and study pins →

European medicine records · 5 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

5586 retrieved · 2 included · 0 excluded · 5584 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Semaglutide"[Title/Abstract] OR "Wegovy"[Title/Abstract] OR "Ozempic"[Title/Abstract] OR "Rybelsus"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:33.424853+00:00 · HTTP 200 · SHA-256 3b62ca5201d3e1967887a0b741a8d33bb9edc649b8dccab137d26118c8211e7f.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.

Showing 25 of 5586 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 37952131 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03574597.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 dabd7cd9d6c08b9c07da39a19d0b48266bfb7ddbbaacefe2e11025d105708245.

  2. PubMed 33567185 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03548935.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 b3cf6a18c3906c27475c4a49d31f5741bf40fa056afc62f07d07fa54dbff28c4.

  3. PubMed 42738873 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42737751 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42736040 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42735880 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42735804 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42735799 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42734721 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42733032 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42732962 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42732434 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42732089 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42730175 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42730115 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42730051 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42729808 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42729683 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42728029 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42727920 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

6 retrieved · 6 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"SEMAGLUTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:26.438298+00:00 · HTTP 200 · SHA-256 c50ccc5ef8704bc1134f7618bfec70c41a9a5c6bd64fede7a52ab00dde77ae30.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 6 of 6 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA209637 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
  2. FDA ANDA220314 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
  3. FDA NDA213182 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
  4. FDA NDA215256 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
  5. FDA NDA218316 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
  6. FDA NDA213051 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Semaglutide", "Wegovy", "Ozempic", "Rybelsus"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/005422 — include: EMA feed product Wegovy; reported status: Authorised. Exact indication and decision documents remain unappraised.
  2. EMA EMEA/H/C/004174 — include: EMA feed product Ozempic; reported status: Authorised. Exact indication and decision documents remain unappraised.
  3. EMA EMEA/H/C/004953 — include: EMA feed product Rybelsus; reported status: Authorised. Exact indication and decision documents remain unappraised.
  4. EMA EMEA/H/C/006426 — include: EMA feed product Kayshild; reported status: Authorised. Exact indication and decision documents remain unappraised.
  5. EMA EMEA/H/C/006279 — include: EMA feed product Kyinsu; reported status: Authorised. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

78 retrieved · 45 included · 0 excluded · 33 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Semaglutide", "Wegovy", "Ozempic", "Rybelsus"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 25 of 78 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 14075 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Public assessment report
  2. EMA 29427 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Summary for the public
  3. EMA 47367 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  4. EMA 47769 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Public assessment report
  5. EMA 49769 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  6. EMA 50994 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  7. EMA 53437 — include: Document linked by EMA product number; content unappraised. Rybelsus-EMEA-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  8. EMA 54265 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-004174-X-0021 : EPAR - Assessment report - Variation
  9. EMA 54415 — include: Document linked by EMA product number; content unappraised. Wegovy : EPAR - Public Assessment Report
  10. EMA 58573 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  11. EMA 58575 — include: Document linked by EMA product number; content unappraised. Rybelsus-EMEA-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  12. EMA 58910 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
  13. EMA 60713 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-5422-II-0009 : EPAR - Assessment Report - Variation
  14. EMA 61952 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-005422-II-0009 : EPAR - Assessment report - Variation
  15. EMA 64756 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-005422-II-0017 : EPAR - Assessment report - Variation
  16. EMA 47766 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - All Authorised presentations
  17. EMA 47768 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Risk management plan
  18. EMA 13667 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  19. EMA 47939 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  20. EMA 7027 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - All Authorised presentations
  21. EMA 69828 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Medicine overview
  22. EMA 72528 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Medicine overview
  23. EMA 72529 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Risk management plan
  24. EMA 72531 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - All authorised presentations
  25. EMA 72532 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Public assessment report

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Semaglutide", "Wegovy", "Ozempic", "Rybelsus"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    783 retrieved · 0 included · 0 excluded · 783 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Semaglutide" OR "Wegovy" OR "Ozempic" OR "Rybelsus" OR "Kayshild" OR "Kyinsu"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:52.609684+00:00 · HTTP 200 · SHA-256 814aea84b1cbf86daa3494307142be5d4fbc028bd00333ab7f8f4530c2dae712.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:54.277422+00:00 · HTTP 200 · SHA-256 972ec5f11faeafdf6e0ec110461396ec17d32998920bc9c1f476f55611810084.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:55.664476+00:00 · HTTP 200 · SHA-256 b3d8895ed88045fa9c8c0b07a64459fea5d9344d881f6a50a550d300b8b66dce.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:57.168807+00:00 · HTTP 200 · SHA-256 2f0200b949109ac5e9c1b291a65d5f144cd3c121edf5e49945e603ff5e9ddc83.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:58.412904+00:00 · HTTP 200 · SHA-256 e0fa80f23d7633ac60dca61538f4f677f477841b1d929e6870199da7b7e6ea5f.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:59.821049+00:00 · HTTP 200 · SHA-256 430bcd2086343c8762b33d8279536cda404c1e3c5fc8b26c126cd89d69d516fc.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:27:01.860109+00:00 · HTTP 200 · SHA-256 10ea128ce764cecba3d428e0f40b48b7a766e9ca2fbf02ef473cdc8925c9f2b4.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:27:03.409534+00:00 · HTTP 200 · SHA-256 f1ac058df0d6369131b680a310a842d943711cddeb9e649ec281262b71371273.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 783 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT00833716 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT06546384 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT06500143 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT06015893 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT06977438 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT07169136 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT07711548 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT07627191 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT05616013 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT07194317 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT06065540 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT02863419 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT05920889 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT07770282 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT01272973 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT03548935 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT05227196 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT07064486 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT06807970 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT03631186 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT07478653 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT05441267 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT05700877 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT07720466 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT04447859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Semaglutide?

    FDA-approved as Ozempic, Rybelsus and Wegovy. The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.↗↗↗↗↗

    The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

    Evidence present

    What records are connected here?

    Evidence lanes
    4
    Source years
    10
    Drugs@FDA applications
    5

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Coverage gaps

    What remains unknown or unsupported?

    All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Semaglutide?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    290Selected dated records
    293Connected citations
    10Populated source years2017–2026
    4/4Record lanes present

    Registered human studies

    Trial composition

    64 of 140 selected trial records include at least one phase value; 70 of 140 include a status value in the retained structured contract.

    1,966 public history versions connect to 96 of these trial records across 13 submitted years. Open the record-history collection →

    3 exact source-declared trial-publication links connect selected NCT and PMID records. Open the exact graph →

    PhasesPhase 3 22Phase 2 19Phase 1 12Phase 4 10Not applicable 4
    Status at observationCompleted 22Recruiting 20Not yet recruiting 15Active, not recruiting 11Enrolling by invitation 2

    A phase value is unavailable here for 76 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 70 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    52 of 108 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesJournal Article 43Letter 6Case Reports 3Editorial 3Observational Study 3Research Support, Non-U.S. Gov't 3Review 3Randomized Controlled Trial 2Clinical Trial, Phase II 1Consensus Statement 1Multicenter Study 1

    Bibliography fields unavailable here for 56 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    5
    FDA Federal Register documents
    13
    DailyMed SPL versions
    19
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    290

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts
    Trial–publication links · 3

    Exact identifier graph

    3 trial-publication links for Semaglutide

    Open the full graph →

    These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.

    Source records by collection · 290 dated records

    Research hub

    Explore the Semaglutide evidence record

    Open all 290 records →
    290Dated records
    4Evidence types
    290Cited public sources
    10Source years

    Change ledger

    Recently changed for Semaglutide

    Open all 298 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Record updated

    ClinicalTrials.gov record NCT06015893

    ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials
    Record updated

    Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.

    PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 1, 2026
    Evidence lane
    Literature metadata
    Record updated

    Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.

    PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    October 9, 2026
    Evidence lane
    Literature metadata

    Official-source collections

    Source records for Semaglutide

    Open the full research atlas →
    PubMed108

    52 with attributed title, venue, publication-date, and type metadata.

    1. Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process.Archives of disease in childhood · 2026 11 03
    2. Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population.Journal of gastroenterology · 2026 10 27
    3. Semaglutide and alcohol use disorder: An evidence gap India must fill.Indian journal of psychiatry · 2026 10 21
    Explore all selected literature →
    ClinicalTrials.gov140

    1,966 public history versions across these dated registry records; status labels apply only to each cited observation.

    1. NCT06015893Registry update November 16, 2026 · current at observation
    2. NCT07935200Registry update November 13, 2026 · current at observation
    3. NCT06299098Registry update November 12, 2026 · completed at observation
    Explore all selected trial records →Explore all public record history →
    Drugs@FDA5

    Original-submission application metadata connected by exact reviewed active-ingredient names.

    1. NDA218316Full FDA chronology · original submission status AP 2025-12-22
    2. NDA215256Full FDA chronology · original submission status AP 2021-06-04
    3. NDA213182Full FDA chronology · original submission status AP 2020-01-16
    4. NDA213051Full FDA chronology · original submission status AP 2019-09-20
    5. NDA209637Full FDA chronology · original submission status AP 2017-12-05
    Explore all selected FDA applications →Explore 50 dated submissions and 109 documents for Semaglutide →
    FDA enforcement reports1

    Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

    1. D-0536-2021Class II · report date 2021-06-02
    Explore all exact FDA enforcement reports →
    DailyMed SPL history19

    Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

    1. SPL version 19Published 2026-06-30 · ZIP SHA-256 a8c57f3e8cf2…
    2. SPL version 18Published 2026-05-22 · ZIP SHA-256 42a72412a3cb…
    3. SPL version 17Published 2026-04-02 · ZIP SHA-256 32ff68a3805c…
    4. SPL version 16Published 2026-03-05 · ZIP SHA-256 121930978afd…
    5. SPL version 15Published 2026-02-12 · ZIP SHA-256 521dffd6648a…
    Explore all DailyMed label versions →

    Evidence types

    Coverage by source year

    Selected records span April 4, 2017 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Organizations and trial records named in cited sources

    Organizations named in cited records

    • U.S. National Library of Medicine1
    • U.S. Food and Drug Administration4,10
    Dated updates connected to this profile · 290

    Updates connected to this profile

    Open the full cross-source timeline →
    1. Clinical trials

      ClinicalTrials.gov record NCT06015893↗

      PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    2. Clinical trials

      ClinicalTrials.gov record NCT07935200↗

      PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    3. Clinical trials

      ClinicalTrials.gov record NCT07112872↗

      PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    4. Clinical trials

      ClinicalTrials.gov record NCT07642635↗

      PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    5. Clinical trials

      ClinicalTrials.gov record NCT07931573↗

      PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    6. Clinical trials

      ClinicalTrials.gov record NCT07931599↗

      PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    7. Literature metadata

      Semaglutide and alcohol use disorder: An evidence gap India must fill.↗

      PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    8. Clinical trials

      ClinicalTrials.gov record NCT06299098↗

      PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    9. Clinical trials

      ClinicalTrials.gov record NCT06778967↗

      PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    10. Clinical trials

      ClinicalTrials.gov record NCT07400107↗

      PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.↗

    11. Literature metadata

      Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use.↗

      PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    12. Literature metadata

      Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process.↗

      PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    Citations

    Sources

    Coverage and sources →

    Numbered markers in the text point here. Each link opens the original public record.

    1. 1
      WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

      DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

    2. 2
      FDA approves higher-dose semaglutide ↗

      U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

    3. 3
      Semaglutide substance identity record ↗

      FDA Global Substance Registration System · Official source · Source checked July 29, 2026

    4. 4
      Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    5. 5
      Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    6. 6
      Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    7. 7
      Drugs@FDA application NDA218316 · original submission status AP · 2025-12-22 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    8. 8
      FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗

      U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

    9. 9
      FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

      U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

    10. 10
      FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

      U.S. Food and Drug Administration · Official source · Source checked November 14, 2026